180 COVID-19 vaccines in development – WHO

Last updated on September 11th, 2021 at 08:25 am

Around 180 vaccines to combat COVID-19 are in development worldwide, consisting of 35 in human trials, the WHO chief stated on Friday.

“No ailment in history has considered such rapid development in research. It’s a testament to the extremely good advances in science and technological know-how the world has made in latest years,” Director-General Tedros Ghebreyesus told journalists in Geneva.

“It must be matched through its ambition to make certain as many humans as possible have get entry to to them.

” When journalists requested about differing claims on vaccines’ arrival, consisting of an aspiration by using US President Donald Trump to have one via October, the WHO’s chief scientist Soumya Swaminathan stated people should consider that “clinical trials take time.”

“We cannot rush them, because you have to gather sufficient data on sufficient variety of humans to satisfy ourselves and to satisfy the regulatory organizations that a particular drug or vaccine is safe,” she said.

Swaminathan said tens of heaps of humans had to sign up in these clinical trials

. “Since a few trials did begin in July, it is viable that we can also begin getting some results, at least interim consequences by the quit of the year.”

Dr. Mike Ryan, the WHO emergencies program director, admitted that growing a vaccine is a race.

“It’s a race towards this virus, and it’s a race to save lives. It’s now not a race between companies. It’s no longer a race between countries. It’s a race to guide public health and the safest and most tremendous way possible.”

He said it was once no longer a opposition between drug agencies which “to their credit” have come together.

“This is a race in opposition to time to race against the virus to race to save lives.”

The novel virus, which surfaced in the Chinese town of Wuhan last December, has infected nearly 28 million people, and claimed more than 905,000 lives in 188 nations and regions.

(AnadoluAgency)